Comparison

Ipamorelin vs GHRP-2: Evidence-Based Comparison

Compare Ipamorelin and GHRP-2: dosing, mechanisms, safety profiles, and research evidence. Citation-backed comparison.

Overview

A comparison of Ipamorelin and GHRP-2 as growth hormone secretagogues, including selectivity, side effect profiles, half-life, and research protocol context.

Compared compounds

Ipamorelin GHRP-2

Overview

Ipamorelin and GHRP-2 are both ghrelin receptor agonists studied for pulsatile growth hormone release, but they are consistently distinguished by selectivity profile. Ipamorelin is generally characterized as a more selective secretagogue with a narrower side-effect window, while GHRP-2 is associated with broader receptor activity and more pronounced ancillary effects.

Mechanism Comparison

Both compounds act on the ghrelin receptor (GHSR-1a), but GHRP-2 is associated with stronger cortisol and prolactin stimulation alongside GH release. Ipamorelin is specifically noted in the research literature for its comparative selectivity, stimulating GH release with minimal impact on cortisol, prolactin, or ACTH, which is a key distinction in protocol planning discussions.

Dosing and Protocol Comparison

Both compounds are typically studied at similar frequency intervals, and both are often compared in the context of pairing with a GHRH analog such as CJC-1295. The choice between them in protocol literature often comes down to tolerability preference and whether the research question requires a cleaner secretagogue signal or accepts the broader hormonal effects associated with GHRP-2.

Evidence Comparison

Ipamorelin has attracted more attention in selective secretagogue protocol discussions, while GHRP-2 has a somewhat longer research history in earlier GH-stimulation studies. Both compounds remain primarily in the preclinical to limited human study range. For research purposes, the selectivity difference is generally the more useful comparison axis than simple evidence volume.

Frequently asked questions

Which is better, Ipamorelin or GHRP-2?

Ipamorelin and GHRP-2 are researched for different contexts, so the better choice depends on study goals, mechanism priorities, and protocol design.

Can you stack Ipamorelin and GHRP-2?

Some researchers evaluate Ipamorelin and GHRP-2 together, but combination design depends on evidence quality, safety considerations, and whether overlapping mechanisms are appropriate for the research question.